# Conference Participant Output: qwen-three-platform-gold-20260908 - visual_single_object

## Boundary Check

1. **Workspace and Path Containment**:
   - Current execution path: `.worktrees/phase5-clinical-facts-profile/.trellis/tasks/09-05-phase55-dual-vlm-page-review`.
   - Read-only access maintained: Inspected only the authorized root-relative artifacts, contracts, harnesses, and image slices.
   - Zero write actions executed: No production paths modified, no source code touched, no background models/servers spawned, no secret/credential leakage.
   - Report delivery contract respected: Returning complete report in stdout; runner persists to `runs/conference/qwen-three-platform-gold-20260908/visual_single_object.md`.

2. **Role and Authority Boundary**:
   - Role: `visual_single_object` (独立视觉审阅).
   - Provider/Model: `pi` / `google-antigravity` / `gemini-3.7-flash` (thinking: `high`).
   - Authority: Advisory and evidence-grounded audit. Codex retains final authority over clinical/regulatory conclusions, visual/browser checks, and production code writes.

---

## Independent Work Product

### 1. Dimension 1: Protocol Native Deconstruction Independent Audit

- **Authoritative Source Protocol**:
  - Source file: `CMS-D001 银屑病2、3期临床方案 v1.0-2025.12.21.docx` (`sha256: 362443131f0d384c82c80f6a37396084f7d3301b51162201749c0488b0f2dd98`).
  - Native Run Manifest: `artifacts/phase55-model-comparison/20260907/protocol-native-runs/d001-glm-low-v1/manifest.json`.
  - Confirmed Protocol Metadata:
    - Protocol Code: `D001-02-002`
    - Project Name: `评价CMS-D001片治疗中度至重度斑块状银屑病成人患者的有效性和安全性的多中心、随机、双盲、安慰剂对照Ⅱ/Ⅲ期临床研究`
    - Official Version: `1.0` (Date: `2025-12-10`, Precision: `day`)
    - Study Phase: `phase_ii`
    - Total Source Block Count: `3581` blocks.

- **Deconstruction Architecture & Contract Invariants**:
  - **Single Source of Truth**: The Word DOCX OOXML is the definitive structural source. Deconstruction must not infer or invent official clause numbers (`IN-xx`, `EX-xx`, `REQ-xx`).
  - **DNF Representation**: Rule expressions map strictly to Disjunctive Normal Form (`DNFGroup` -> `Atom`) with bounded atomic groups (`DNF_WIRE_MAX_GROUPS = 64`, `DNF_WIRE_MAX_ATOMS_PER_GROUP = 64`).
  - **Deterministic Parent-Rule Segmentation**: The architecture enforces strict parent-rule isolation (`SEMANTIC_BATCH_MAX_INPUT_TOKENS = 16_000`). Semantic repairs must be local and bounded to affected parent rules without cross-rule context leakage.
  - **Interpretation & Anchors**: Explicit anchor types (`screening`, `baseline`, `randomization`, `first_dose`) are strictly separated from prospective windows (`treatment_period`, `study_period`).

---

### 2. Dimension 2: Visual Ground Truth & Fixed ClausePack Clinical Source Audit

A direct visual audit was conducted on the prioritized source images in `product-input-v2` (SAR project) and `product-source-d001-sa07007-v1` (D001 project).

#### A. Critical Defect in Unit Gold: SAR Index 9 Blood Routine (`gold-sar-lab-page9-units-v2.json`) vs Image (`5245d99ccde3...`)

- **Visual Evidence on SAR Page 9**:
  - **Typesetting / Column Shift**: The hospital printout (`BC6800PLUS` analyzer, `2025-08-15`) exhibits severe layout distortion and field shifting on the right-hand column (items 16–29):
    1. **Line 17 (MCHC)**: The result value `333` is concatenated directly onto the Chinese name: `★红细胞平均血红蛋白浓度333`, resulting in an empty/shifted result column.
    2. **Line 18 (RDW-SD / W-SD)**: Printed code is truncated to `W-SD`, name is `红细胞分布宽度-SD值`, result is `40.1`, reference range is `37.0--54.0`. **The printed `单位` (Unit) column is completely BLANK / EMPTY.**
    3. **Line 19 (RDW-CV / W-CV)**: Printed code is `W-CV`, name is `红细胞分布宽度-CV值`, result is `13.2`, reference range is `11.0--16.0`, unit is printed as `%`.
    4. **Line 28 (NRBC / 有核红细胞数目)**: Unit cell is completely BLANK.
    5. **Line 29 (NRBC% / 有核红细胞百分比)**: Unit cell is completely BLANK.
  - **Post-it Note Occlusion**: A physical sticky note is pasted across the middle of the table. Handwritten text on the note: **`NCS`** in pen. A line points from the reference range of rows 5–6 towards the note.
  - **Signatures & Timestamps**:
    - 检验者 (Tester): `杜立` (Handwritten signature).
    - 审核者 (Reviewer): `董静` (Signature/stamp).
    - Sampling time: `2025-08-15 9:46`, Receive time: `9:54`, Report time: `10:12`.

- **Audit Finding & Defect in `gold-sar-lab-page9-units-v2.json`**:
  - `gold-sar-lab-page9-units-v2.json` line 6 claims: `"correction": "RDW-SD is printed as percent, not fL. NRBC and NRBC% have blank unit cells and are excluded..."` and line 13 sets `"RDW-SD": "%"`.
  - **Ground Truth Inconsistency**: Direct visual inspection proves that `RDW-SD` has **NO printed unit** on the page. The `%` symbol belongs exclusively to `RDW-CV` on the line below.
  - **Impact**: Setting `"RDW-SD": "%"` in gold-v2 creates an ungrounded ground-truth defect. A model that faithfully outputs `null` or empty string for RDW-SD's unit is penalized, while a hallucinating model that copies the `%` from the adjacent row is rewarded.

---

#### B. SAR Index 17 Biochemistry Report (`gold-sar-biochemistry-page17.json`) vs Image (`6566ecfcee72...`)

- **Visual Evidence on SAR Page 17**:
  - **34 Printed Biochemistry Items**: Fully validated against `gold-sar-biochemistry-page17.json`. All 34 items match printed numbers, units, and references:
    - Electrolytes & Renal: K `4.35`, Na `137.8`, Cl `101.3`, Ca `2.30`, UREA `4.28`, CREA `79`, UA `263`, GFR `99`.
    - Liver Enzymes & Proteins: TP `78.3`, ALB `49.3`, GLB `29.0`, A/G `1.7`, AST `34.9`, ALT `57.8↑`, AST/ALT `0.6`, GGT `146↑`, TBIL `30.5↑`, DBIL `8.7↑`, IB `21.8↑`, ALP `84`, MAO `4.20`, TBA `1.4`, CHE `10080`, PA `288.4`, ADA `13.5`, 5'-NT `15.1↑`.
    - Lipids & Glucose: GLU `5.60`, CHOL `3.67`, TG `1.12`, HDL-C `1.20`, LDL-C `1.95`, VLDL `0.52`, IP `1.26`, Mg `0.88`.
  - **Handwritten Annotations & Overlays**:
    - Top yellow Post-it: Handwritten in black ink: `CS 肝功能不全` (Clinical Significance: Liver dysfunction).
    - Bottom yellow Post-it: Handwritten in black ink: `- CS 肝功异常` (CS Liver function abnormal).
  - **Signatures & Timestamps**:
    - 检验者 (Tester): `王猛` (Handwritten signature).
    - 审核者 (Reviewer): `曹爽` (Handwritten signature).
    - Sampling: `2025-08-08 10:13`, Receive: `10:15`, Report: `11:17`.
  - **Clinical Audit Verification**: The researcher's handwritten clinical judgment `CS 肝功能不全` directly attaches to the liver panel elevations (ALT 57.8↑, GGT 146↑, TBIL 30.5↑, DBIL 8.7↑, IB 21.8↑, 5'-NT 15.1↑). In accordance with R3 engineering design §11 & §16, this handwritten notation is an explicit clinical judgment, not an automatic eligibility failure or an unverified artifact.

---

#### C. SAR Index 18 HBV-DNA Report Image (`43c9653b1b6a...`)

- **Visual Evidence on SAR Page 18**:
  - Institution: 河北省中医院检验中心 (Molecular Biology Report).
  - Test Item: `★HBV-DNA定量` (Fluorescence quantitative PCR, SLAN-96P).
  - Result: **`未检测到靶基因`** (Target gene not detected).
  - Unit: `IU/mL`.
  - Lower Limit of Quantitation: `2.00E+01` (Detection limit `1.00E+01 IU/mL`).
  - Timestamps: Sampling `2025-08-15 9:46`, Receive `9:55`, Report `14:57`.
  - Signatures: 检验者 `王金伟`, 审核者 `赵玉梅`.
  - **Clinical Nuance**: "未检测到靶基因" is a qualitative result indicating concentration below `1.00E+01 IU/mL`. It is not a numeric `0` and does not negate past hepatitis B exposure (patient was Anti-HBs+, Anti-HBe+, Anti-HBc+ on page 7).

---

#### D. SAR Index 0 Outpatient Medical Record Page 1 Image (`c129ecdbea99...`)

- **Visual Evidence on SAR Page 0**:
  - Hospital: 河北省中医院 门(急)诊病历 (`2025-08-08 09:12`).
  - Patient Demographics: Male, DOB `1973-08-11`, Age 51, Han ethnicity.
  - Chief Complaint: Allergic rhinitis symptoms since `2000` (25 years duration).
  - Present Illness Timeline & Medications:
    - `2025-04-05`: Flare-up, diagnosed at Hebei Medical University First Hospital. Prescribed:
      1. 枸地氯雷他定胶囊 (Desloratadine citrate disodium), `8.8mg`, qd.
      2. 孟鲁司特钠片 (Montelukast sodium), `10mg`, qd.
      3. 注射用奥马珠单抗 (Omalizumab for injection), `300mg`, subcutaneous injection. Response: "治疗效果不佳" (Poor therapeutic effect).
    - `2025-08-08`: Presenting visit to Hebei Provincial Hospital of TCM for trial screening under MG-K10 protocol.

---

#### E. D001 Prioritized Pages: Index 0, 42, 44

1. **D001 Index 0 (Pharmacy Receipt, Image `e02ac4332884...`)**:
   - Header: `怀庆大药房`. Receipt No: `10020260302476352`.
   - Transaction Time: `2026-03-02 16:35:11`.
   - Item: `1.异烟肼片` (Isoniazid Tablets), Spec: `0.1g*100 片/盒`, Expiration: `2028-08-29`, Quantity: `1`, Amount: `6.20` RMB.
   - Clinical Verification: Proves self-purchase/exposure to Isoniazid (anti-tuberculosis medication) on `2026-03-02`. No physician diagnosis is on this receipt.

2. **D001 Index 42 (T-SPOT Report, Image `f5159a54ff8c...`)**:
   - Title: `结核感染T细胞斑点试验报告` (Adicon / Shijiazhuang TCM Hospital).
   - Numerical Results:
     - 阴性对照孔 (Negative Control): `0`
     - 抗原检测孔 (Antigen Detection): `6`
     - 阳性对照孔 (Positive Control): `正常`
   - Printed Categorical Result: `阳性` (Positive, yellow highlight).
   - Remarks / Footnote: **`检测结果为灰区, 请结合临床`** (Gray zone, please correlate clinically).
   - Timestamps: Collection `2026-03-12 09:48`, Received `2026-03-13 01:00`, Report `2026-03-14 12:03`.
   - Handwritten Signature: `郝[某] 2026.3.16`.
   - **Clinical Discrepancy Inherent to Document**: The report prints `阳性` based on the formula $6 - 0 \ge 6$, but the remark explicitly flags `灰区`. An audit system must retain both the categorical result and the gray-zone qualifier rather than silently suppressing the remark.

3. **D001 Index 44 (BSA & PGA CRF Pages 2–3, Image `ef3a26a95de4...`)**:
   - Protocol No: `D001-02-002-项目专用版`, Version `V1.0-20260108`, Pages 2 & 3 of 5.
   - **体表面积 (BSA) (Palm Method)**:
     - Head: `2` palms, Upper Limbs: `4` palms, Trunk: `4` palms, Lower Limbs: `7` palms.
     - **Total Affected BSA**: **`17 %`** (Handwritten). Assessment end time: `11:58`.
   - **医生整体评估 (PGA)**:
     - Erythema (E): `3` (Red).
     - Induration (I): `2` (Mild but definite elevation).
     - Scaling (S): `3` (Mostly coarse scaling).
     - **Calculated PGA Score**: $\frac{3 + 2 + 3}{3} = \frac{8}{3} = \mathbf{2.67}$ (Handwritten).
     - Categorical Tier: $\ge 2.50 \implies \mathbf{3}$ (**中度 / Moderate**). Assessment end time: `12:05`.
     - Handwritten signature/date: `2024.3.12` / `2026.3.16`.

---

## Evidence And Assumptions

### 1. Evidence Matrix (Direct Visual Observation vs Gold Standard)

| Document & Index | Visual Observation (Ground Truth) | Current Gold / Harness Assertion | Audit Verdict | Impact & Nature |
|---|---|---|---|---|
| **SAR Index 9 (Lab Page 9)** | RDW-SD printed unit cell is **BLANK**; RDW-CV unit is `%`; MCHC printed as `浓度333` | `gold-sar-lab-page9-units-v2.json` asserts `"RDW-SD": "%"` | **DEFECT in Gold v2** | Faulty ground truth; penalizes correct OCR/VLM extraction of blank unit. |
| **SAR Index 9 (Lab Page 9)** | Sticky note with handwritten `NCS` over rows 5–7 and 18–23 | Excluded from printed item evaluation | **CONFIRMED** | True physical occlusion; code prefixes truncated. |
| **SAR Index 17 (Biochemistry)** | 34 printed numeric items match; 2 yellow Post-its with `CS 肝功能不全` | `gold-sar-biochemistry-page17.json` contains 34 items | **VALIDATED** | Exact match on 34 printed values; handwritten notes capture CS. |
| **SAR Index 18 (HBV-DNA)** | Result: `未检测到靶基因`, unit `IU/mL`, lower limit `2.00E+01` | Product input fixture | **VALIDATED** | Qualitative PCR lower-limit result; must not be converted to float 0. |
| **SAR Index 0 (Outpatient)** | 4 distinct dates, 3 prior drugs, poor response to Omalizumab | Product input fixture | **VALIDATED** | Rich longitudinal medical history verified. |
| **D001 Index 0 (Receipt)** | Isoniazid tablets purchased `2026-03-02 16:35:11` | Source fixture | **VALIDATED** | Objective drug exposure evidence without medical diagnosis. |
| **D001 Index 42 (T-SPOT)** | Numerical spots 0 & 6; printed `阳性`; remark `检测结果为灰区` | Source fixture | **VALIDATED** | Visual source contains inherent dual status (`阳性` + `灰区`). |
| **D001 Index 44 (BSA/PGA)** | BSA handwritten `17%`; PGA E3/I2/S3 handwritten mean `2.67` (Moderate) | Source fixture | **VALIDATED** | Primary scale data and investigator calculation verified. |

### 2. Assumptions vs Facts

- **Assumption Challenged**: "A model with high union recall is ready for production pairing."
  - **Fact**: Pairing analysis shows GLM low + MLX Serve high achieved 34/34 union on biochemistry, but yielded **0 adopted keys** in product reconciliation due to lack of source-field alignment and exact location keying.
- **Assumption Challenged**: "Missing investigator written judgment on abnormal lab tests halts the review pipeline."
  - **Fact**: Under R3 design §16 (2026-09-06 user ruling), missing investigator judgment is recorded as an unresolved clinical finding / pending investigator action, and does NOT block the generation of the review report or pause the pipeline.
- **Assumption Challenged**: "RDW-SD was printed as `%`."
  - **Fact**: Visual proof shows RDW-SD unit cell is completely blank. The `%` belongs to RDW-CV.

---

## Risks, Gaps, And Verification Needs

### 1. High-Impact Defects & Risks

1. **Defect in `gold-sar-lab-page9-units-v2.json`**:
   - **Risk**: Automated evaluation harnesses using `gold-sar-lab-page9-units-v2.json` will register false negative errors against any VLM that accurately detects the blank unit for RDW-SD.
   - **Remediation**: Issue `gold-sar-lab-page9-units-v3.json` moving `RDW-SD` into the `excluded / blank` list alongside `NRBC` and `NRBC%`, or allow `["", null, "%"]` as acceptable tolerances in the unit evaluation script.

2. **Severe Typesetting Concatenation in Hospital Printouts**:
   - **Risk**: In SAR page 9, `★红细胞平均血红蛋白浓度333` merges the name and numerical result. VLMs frequently fail either by truncating the name or by missing the numeric value `333`.
   - **Remediation**: Normalizer extraction rules must handle name-value suffix concatenation as a recognized pattern for Chinese LIS reports without hallucinating missing rows.

3. **Inherent Clinical Contradiction on Single Source Pages (e.g. D001 Index 42 T-SPOT)**:
   - **Risk**: Models may output only `阳性` and omit `检测结果为灰区`, or vice versa.
   - **Remediation**: The reconciliation engine must require extraction of both the categorical result and the remarks field when remarks qualify the diagnostic certainty.

---

### 2. Precise Bounded Questions for Codex

1. **Question 1 (Gold Standard Correction)**:
   - *Question*: Shall we update the gold benchmark from `gold-sar-lab-page9-units-v2.json` to `gold-sar-lab-page9-units-v3.json` to formally mark `RDW-SD`'s unit as blank/unprinted (matching visual reality), thereby preventing false penalization of compliant models?
   - *Why it matters*: Benchmarking accuracy and ranking integrity are distorted if compliant models are penalized for not hallucinating `%` on a blank cell.
   - *Safe provisional path*: In evaluation metrics, treat `RDW-SD` unit as optional/excluded (same as `NRBC` and `NRBC%`).

2. **Question 2 (Reconciliation of Inherent Source Ambiguity)**:
   - *Question*: For D001 Index 42 (T-SPOT), should the dual-read reconciliation contract mandate capturing both the categorical `阳性` and the remark `灰区`, defining single-attribute capture as an incomplete observation?
   - *Why it matters*: In clinical trials, ignoring a laboratory "gray zone" warning can lead to inappropriate subject enrollment.
   - *Safe provisional path*: Preserve both observations in the reconciliation record as co-existing source attributes.

---

## Recommended Next Step

1. **Immediate (Gold Standard Alignment)**:
   - Update `gold-sar-lab-page9-units-v2.json` to `v3` to reflect the blank unit cell of `RDW-SD` demonstrated by this visual audit.
2. **Harness & Normalizer Calibration**:
   - Ensure the dual-VLM harness evaluates structural extraction against verified visual reality (including blank unit tolerances and concatenated name-value tokens).
3. **Reconciliation Engine Integration**:
   - Proceed with connecting the verified visual observations (SAR 34 biochemistry items, 21 lab unit slice, D001 T-SPOT and BSA/PGA scores) to the R3 two-round reconciliation and clinical action center pipeline without altering source code in this pass.
